Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Targeting the IL-6/JAK/STAT3 signalling axis in cancerTargeting the IL-6/JAK/STAT3 signalling axis in cancer, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.8The interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In this Review, the authors describe the clinical potential of agents designed to inhibit the IL-6/JAK/STAT3 signalling pathway, either alone or in combination with other agents, in patients with cancer.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Daniel E. Johnson Rachel A. O ' Keefe Jennifer R. Grandis Source Type: research
More News: Cancer | Cancer & Oncology